These Compromises Destroy Public Trust: When the Medical Regulator Partners with Activists, By Brian Simpson
Australia's peak medical regulator, the Australian Health Practitioner Regulation Agency (AHPRA), is facing serious accusations of ideological capture. FOI documents reveal it has embedded itself in a formal partnership with ACON (formerly the NSW AIDS Council), one of the country's most influential trans lobby groups that actively promotes gender-affirming care for minors. AHPRA's own boss, Justin Untersteiner, has stated that engagement with ACON and Rainbow Health Australia guides "the way we regulate and fulfil our purpose of ensuring the preservation of public safety."
This isn't passive "inclusion." AHPRA has developed a National Scheme LGBTIQA+ Equity and Inclusion Strategy explicitly drawing on ACON's frameworks (Rainbow Tick and Australian Workplace Equality Index). Internal papers show plans to reform regulatory processes, external engagement, and board portfolios over 3-5 years to align with these advocacy standards.
Real-World Consequences
The partnership coincides with a pattern of actions that critics say chills dissent while protecting affirmative practitioners:
Disciplining psychiatrists, one investigated for sharing a news article expressing concerns about youth treatments.
Registering a transgender doctor as "female" for work in NSW hospitals.
Doctors report a climate where professionals are "too scared to dissent," even privately, fearing complaints from activists funnelled through a regulator seen as aligned with one side. A coalition of 46 practitioners has pleaded with AHPRA and the National Health Practitioner Ombudsman to sever ties, warning of perceived bias in a contested field where evidence for puberty blockers and hormones in minors remains weak and under review.
Why This Undermines Public Relations — and Safety
Regulators derive authority from perceived neutrality and competence. When the body tasked with protecting patients partners with an advocacy group pushing a specific ideological model in a highly disputed area of medicine, it signals capture. AHPRA isn't just promoting workplace inclusion internally; documents show it intends these frameworks to shape how it regulates care delivery and practitioner speech.
Public trust erodes fast in such cases. Parents of gender-distressed children, women's rights groups, and concerned clinicians already question whether complaints processes are impartial. The ABC recently severed its own long-standing ACON ties after bias concerns — a cautionary tale AHPRA appears to be ignoring.
This fits a broader Western pattern: institutions (health boards, schools, media) embedding activist frameworks under "equity" banners, then struggling to maintain credibility when evidence shifts (as seen in the UK's Cass Review and European countries tightening youth gender protocols). In medicine, the stakes are higher — irreversible interventions on minors, free speech for doctors, and informed consent.
AHPRA's statutory duty is public safety through evidence-based, impartial regulation — not advancing contested social ideologies. Partnerships like this don't foster smooth public relations; they breed scepticism, division, and legitimate fears that ideology is trumping patient welfare. Restoring confidence requires transparency, distance from lobby groups, and a renewed focus on clinical evidence over activism. Without that, trust in the entire regulatory system frays further.
